RADIUS is ready for an upward rally after being beaten down
RADIUS is one of my most promising stock at the moment.
-From a micro-technical point of view, we see signs of trend reversal.
Two morning stars and two head & shoulders patterns (switch time frames) recently.
-From a macro-technical and fundamental perspective, there are several reasons that augment the reversal probability:
RADIUS was beaten down (too much).
It is lower than months and even years ago while, at the same time, having stronger fundamentals.
Radius is still in the innovation race as it entered in the Phase III of a new osteoporosis treatment (and IMO it is pretty incredible that the stock didn't move the day it was announced!)
Source: globenewswire.com/news-release/2020/05/27/2039144/0/en/Pivotal-Phase-III-trial-of-abaloparatide-SC-in-Japanese-women-and-men-with-osteoporosis-achieves-primary-endpoint.html
-From an even more macro perspective, the stock should be fueled by investors that bet on stocks that provide products that will be more demanded by an ageing population (osteoporosis).
-From a micro-technical point of view, we see signs of trend reversal.
Two morning stars and two head & shoulders patterns (switch time frames) recently.
-From a macro-technical and fundamental perspective, there are several reasons that augment the reversal probability:
RADIUS was beaten down (too much).
It is lower than months and even years ago while, at the same time, having stronger fundamentals.
Radius is still in the innovation race as it entered in the Phase III of a new osteoporosis treatment (and IMO it is pretty incredible that the stock didn't move the day it was announced!)
Source: globenewswire.com/news-release/2020/05/27/2039144/0/en/Pivotal-Phase-III-trial-of-abaloparatide-SC-in-Japanese-women-and-men-with-osteoporosis-achieves-primary-endpoint.html
-From an even more macro perspective, the stock should be fueled by investors that bet on stocks that provide products that will be more demanded by an ageing population (osteoporosis).
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。